149 related articles for article (PubMed ID: 35199053)
1.
Minari R; Valentini S; Madeddu D; Cavazzoni A; La Monica S; Lagrasta CAM; Bertorelli R; De Sanctis V; Fassan P; Azzoni C; Bottarelli L; Frati C; Gnetti L; Facchinetti F; Petronini PG; Alfieri R; Romanel A; Tiseo M
JTO Clin Res Rep; 2022 Feb; 3(2):100278. PubMed ID: 35199053
[TBL] [Abstract][Full Text] [Related]
2. SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors.
Sato H; Kubota D; Qiao H; Jungbluth A; Rekhtman N; Schoenfeld AJ; Yu HA; Riely GJ; Toyooka S; Lovly CM; Paik P; Ladanyi M; Fan PD
JCO Precis Oncol; 2022 Aug; 6():e2200088. PubMed ID: 35952318
[TBL] [Abstract][Full Text] [Related]
3. Durable clinical response to ALK tyrosine kinase inhibitors in
Hu H; Dai H; Ding L
Transl Cancer Res; 2022 Aug; 11(8):2967-2972. PubMed ID: 36093526
[TBL] [Abstract][Full Text] [Related]
4. Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs.
Leporati R; Miliziano D; Beninato T; Mazzeo L; Manglaviti S; Brambilla M; Occhipinti M; Prelaj A; Proto C; Lo Russo G
Tumori; 2024 Apr; ():3008916241246659. PubMed ID: 38623748
[TBL] [Abstract][Full Text] [Related]
5. Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC.
Yun KM; Bazhenova LA
Cancer Manag Res; 2022; 14():843-850. PubMed ID: 35250311
[TBL] [Abstract][Full Text] [Related]
6. Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of
Urbanska EM; Sørensen JB; Melchior LC; Costa JC; Santoni-Rugiu E
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325863
[No Abstract] [Full Text] [Related]
7. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT; Felip E; Bauer TM; Besse B; Navarro A; Postel-Vinay S; Gainor JF; Johnson M; Dietrich J; James LP; Clancy JS; Chen J; Martini JF; Abbattista A; Solomon BJ
Lancet Oncol; 2017 Dec; 18(12):1590-1599. PubMed ID: 29074098
[TBL] [Abstract][Full Text] [Related]
8. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis.
Wang L; Sheng Z; Zhang J; Song J; Teng L; Liu L; Li Q; Wang B; Li B
J Chemother; 2022 Apr; 34(2):87-96. PubMed ID: 34139965
[TBL] [Abstract][Full Text] [Related]
9. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
Lin YT; Chiang CL; Hung JY; Lee MH; Su WC; Wu SY; Wei YF; Lee KY; Tseng YH; Su J; Chung HP; Lin CB; Ku WH; Chiang TS; Chiu CH; Shih JY
Eur J Cancer; 2021 Oct; 156():1-11. PubMed ID: 34392186
[TBL] [Abstract][Full Text] [Related]
10. Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors.
Verdura S; Encinar JA; Teixidor E; Segura-Carretero A; Micol V; Cuyàs E; Bosch-Barrera J; Menendez JA
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551587
[TBL] [Abstract][Full Text] [Related]
11. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.
Yamaguchi N; Lucena-Araujo AR; Nakayama S; de Figueiredo-Pontes LL; Gonzalez DA; Yasuda H; Kobayashi S; Costa DB
Lung Cancer; 2014 Jan; 83(1):37-43. PubMed ID: 24199682
[TBL] [Abstract][Full Text] [Related]
12. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
13. Rapid response to fifth-line brigatinib plus entrectinib in an
Li D; Zhu Y; Song J; Yang D; Cui S; Liu X; Wang L; Zhang J; Pan E; Dai Z
Front Oncol; 2024; 14():1339511. PubMed ID: 38699646
[TBL] [Abstract][Full Text] [Related]
14. Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.
Descourt R; Pérol M; Rousseau-Bussac G; Planchard D; Mennecier B; Wislez M; Cadranel J; Cortot AB; Guisier F; Galland L; Do P; Schott R; Dansin É; Arrondeau J; Auliac JB; Geier M; Chouaïd C
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406523
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of lorlatinib in a lung adenocarcinoma patient with a novel ALK G1202L mutation: a case report.
Meng Z; Li T; Wang P; Lizaso A; Huang D
Cancer Biol Ther; 2021 Jan; 22(1):1-4. PubMed ID: 33380260
[TBL] [Abstract][Full Text] [Related]
16. Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice.
Passaro A; Lazzari C; Karachaliou N; Spitaleri G; Pochesci A; Catania C; Rosell R; de Marinis F
Onco Targets Ther; 2016; 9():6361-6376. PubMed ID: 27799783
[TBL] [Abstract][Full Text] [Related]
17. ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib.
Kim ES; Barlesi F; Mok T; Ahn MJ; Shen J; Zhang P; Ou SI
Future Oncol; 2021 May; 17(14):1709-1719. PubMed ID: 33569983
[TBL] [Abstract][Full Text] [Related]
18.
Shaw AT; Solomon BJ; Besse B; Bauer TM; Lin CC; Soo RA; Riely GJ; Ou SI; Clancy JS; Li S; Abbattista A; Thurm H; Satouchi M; Camidge DR; Kao S; Chiari R; Gadgeel SM; Felip E; Martini JF
J Clin Oncol; 2019 Jun; 37(16):1370-1379. PubMed ID: 30892989
[TBL] [Abstract][Full Text] [Related]
19. Primary resistance to ALK inhibitors in
Siblini L; Schott R; Trensz P; Pencreach E; Bender L
Transl Lung Cancer Res; 2023 Nov; 12(11):2342-2346. PubMed ID: 38090529
[TBL] [Abstract][Full Text] [Related]
20. The Potent ALK Inhibitor Brigatinib (AP26113) Overcomes Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in Preclinical Models.
Zhang S; Anjum R; Squillace R; Nadworny S; Zhou T; Keats J; Ning Y; Wardwell SD; Miller D; Song Y; Eichinger L; Moran L; Huang WS; Liu S; Zou D; Wang Y; Mohemmad Q; Jang HG; Ye E; Narasimhan N; Wang F; Miret J; Zhu X; Clackson T; Dalgarno D; Shakespeare WC; Rivera VM
Clin Cancer Res; 2016 Nov; 22(22):5527-5538. PubMed ID: 27780853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]